Table 2.

Primary and secondary outcome measures analysis.

	Active treatment	Placebo	Difference AT - Placebo
	Mean ±SD	Mean ±SD	Estimate (95% CI)	p
AS total score	−7.5 ± 6.9	−2.8 ± 5.7	−4.71 (−9.68 to 0.25)	0.062
NPI apathy	−1.9 ± 2.2	0 ± 2.7	−1.92 (−3.88 to 0.02)	0.053
PD-CRS total score	1.5 ± 8.9	−4.6 ± 10.6	6.21 (−1.42 to 13.8)	0.306
PD-CFRS	−0.5 ± 2.5	−0.1 ± 2.1	−0.33 (−2.24 to 1.57)	0.722
HAM-D	−1.5 ± 6.6	−0.9 ± 4.1	−0.57 (−4.85 to 3.7)	0.786
UPDRS-III	−3.6 ± 8	2.5 ± 10.5	−6.14 (−13.4 to 1.11)	0.094
PDQ-39	−5.6 ± 19.1	−0.6 ± 12.5	6.95 (−18.6 to 6.1)	0.312
P-CGI	4.08 ± 2.1	4.5 ± 1.9	−0.46 (−2.98 to 1.15)	0.562
P-CGI-QOL	3.08 ± 2.1	2.52 ± 2.1	0.66 (−1.03 to 2.35)	0.428
CGI	4 ± 1.5	3.5 ± 1.5	0.42 (−1.34 to 2.19)	0.607